These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Baptista T; Kin NM; Beaulieu S; de Baptista EA Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268 [TBL] [Abstract][Full Text] [Related]
4. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. Basile VS; Masellis M; McIntyre RS; Meltzer HY; Lieberman JA; Kennedy JL J Clin Psychiatry; 2001; 62 Suppl 23():45-66. PubMed ID: 11603885 [TBL] [Abstract][Full Text] [Related]
5. Management of atypical antipsychotic drug-induced weight gain: focus on metformin. Miller LJ Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423 [TBL] [Abstract][Full Text] [Related]
6. Weight change with atypical antipsychotics in the treatment of schizophrenia. Haddad P J Psychopharmacol; 2005 Nov; 19(6 Suppl):16-27. PubMed ID: 16280334 [TBL] [Abstract][Full Text] [Related]
7. Antipsychotic induced weight gain in schizophrenia:mechanisms and management. Rege S Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255 [TBL] [Abstract][Full Text] [Related]
9. Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Le Hellard S; Theisen FM; Haberhausen M; Raeder MB; Fernø J; Gebhardt S; Hinney A; Remschmidt H; Krieg JC; Mehler-Wex C; Nöthen MM; Hebebrand J; Steen VM Mol Psychiatry; 2009 Mar; 14(3):308-17. PubMed ID: 18195716 [TBL] [Abstract][Full Text] [Related]
10. Management of weight gain in patients with schizophrenia. Aquila R J Clin Psychiatry; 2002; 63 Suppl 4():33-6. PubMed ID: 11913674 [TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. Lieberman JA J Clin Psychiatry; 1996; 57 Suppl 11():68-71. PubMed ID: 8941173 [TBL] [Abstract][Full Text] [Related]
14. [Atypical antipsychotic induced weight gain and metabolic disorders]. Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331 [TBL] [Abstract][Full Text] [Related]
16. [Weight gain from atypical neuroleptics--an underreported adverse effect?]. Wetterling T Fortschr Neurol Psychiatr; 2000 Dec; 68(12):546-56. PubMed ID: 11200858 [TBL] [Abstract][Full Text] [Related]
17. The role of histaminergic H1 and H3 receptors in food intake: a mechanism for atypical antipsychotic-induced weight gain? Deng C; Weston-Green K; Huang XF Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):1-4. PubMed ID: 19922755 [TBL] [Abstract][Full Text] [Related]
18. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Monteleone P; Martiadis V; Maj M Psychiatr Clin North Am; 2009 Dec; 32(4):775-94. PubMed ID: 19944883 [TBL] [Abstract][Full Text] [Related]
19. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group]. Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V; Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268 [TBL] [Abstract][Full Text] [Related]
20. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management. Baptista T; De Mendoza S; Beaulieu S; Bermúdez A; Martinez M Metab Syndr Relat Disord; 2004; 2(4):290-307. PubMed ID: 18370698 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]